NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said today that it has signed separate research and service agreements with pharma firm Daiichi Sankyo and French research institute Centre Léon Bérard.
Under the first agreement, HTG will perform work for Daiichi Sankyo in HTG’s VERI/O laboratory. The initial project includes the development of a custom assay to detect nearly 3,000 mRNA targets using the HTG EdgeSeq technology.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?